Bigatab™

Brigatinib INN Film Coated Tablet

DESCRIPTION

Bigatab™ is a preparation of Brigatinib. Brigatinib is a tyrosine kinase inhibitor with in-vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice.

INDICATIONS

Indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

DOSAGE AND ADMINISTRATION

90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. Administer Brigatinib until disease progression or unacceptable toxicity. To be dispensed by the prescription of a registered physician.

If Brigatinib is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose.

Brigatinib may be taken with or without food. Instruct patients to swallow tablets whole. Do not crush or chew tablets.

If a dose of Brigatinib is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose of Brigatinib at the scheduled time.

• Dose Reduction:

Dosage	Dosage Reduction		
	First	Second	Third
90 mg once daily	60 mg once daily	permanently discontinue	-
180 mg once daily	120 mg once daily	90 mg once daily	60 mg once daily

CONTRAINDICATIONS

None

SIDE EFFECTS

- Diarrhea, nausea, vomiting
- Fatigue
- Rash
- Cough, dyspnea
- Myalgia
- Headache
- Hypertension
- Bradycardia
- Pancreatitis
- Hyperglycemia
- Lungs Problem

WARNINGS & PRECAUTIONS

Monitor for new or worsening respiratory symptoms, particularly during the first week of treatment. Withhold Brigatinib for new or worsening respiratory symptoms and promptly evaluate for ILD/pneumonitis. Upon recovery, either dose reduce or permanently discontinue Brigatinib.

Monitor blood pressure after 2 weeks and then at least monthly during treatment. For severe hypertension, withhold Brigatinib, then dose reduce or permanently discontinue.

Monitor heart rate and blood pressure regularly during treatment. If symptomatic, withhold Brigatinib, then dose reduce or permanently discontinue.

Withhold Brigatinib until recovery to Grade 1 or baseline, then resume at the next lowerdose
Creatine Phosphokinase (CPK) Elevation: Withhold Brigatinib until recovery to Grade 1 or less (less than or equal to 2.5 × ULN)

Visual Disturbance: Advise patients to report visual symptoms. Withhold Brigatinib and obtain ophthalmologic evaluation, then dose reduce or permanently discontinue Brigatinib.

Pancreatic Enzymes Elevation: Monitor lipase and amylase levels regularly during treatment. Based on the severity, withhold Brigatinib, then resume or reduce dose.

Hyperglycemia: Assess fasting serum glucose prior to starting Brigatinib and regularly during treatment. If not adequately controlled with optimal medical management, withhold Brigatinib, then consider dose reduction or permanently discontinue, based on severity.

DRUG INTERACTIONS

CYP3A Inhibitors: Avoid coadministration of Brigatinib with strong or moderate CYP3A inhibitors. If coadministration of a strong or moderate CYP3A inhibitor is unavoidable, reduce the dose of Brigatinib.

CYP3A Inducers: Avoid coadministration of Brigatinib with strong or moderate CYP3A inducers. If coadministration of a strong or moderate CYP3A inducer is unavoidable, increase the dose of Brigatinib.

USE IN PREGNANCY AND LACTATION

There are no clinical data on the use of Brigatinib in pregnant women. There are no data regarding the secretion of Brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with Brigatinib and for 1 week following the final dose.

STORAGE

Do not store above 30 °C temperature. Keep away from light and wet place. Keep out of reach of children.

PACKAGING

Bigatab™ 90 Tablet: Box containing 3 strips of 10 tablets each. Each film coated tablet contains Brigatinib INN 90 mg.

SK+F ONCOLOGY

Manufactured by
ESKAYEF PHARMACEUTICALS LIMITED
RUPGANJ, NARAYANGANJ, BANGLADESH
TM TRADEMARK
R/PM1781 V01